Advertisement
New Zealand markets closed
  • NZX 50

    11,755.17
    +8.59 (+0.07%)
     
  • NZD/USD

    0.6021
    -0.0013 (-0.21%)
     
  • NZD/EUR

    0.5584
    -0.0010 (-0.18%)
     
  • ALL ORDS

    8,022.70
    +28.50 (+0.36%)
     
  • ASX 200

    7,749.00
    +27.40 (+0.35%)
     
  • OIL

    78.20
    -1.06 (-1.34%)
     
  • GOLD

    2,366.90
    +26.60 (+1.14%)
     
  • NASDAQ

    18,161.18
    +47.72 (+0.26%)
     
  • FTSE

    8,433.76
    +52.41 (+0.63%)
     
  • Dow Jones

    39,512.84
    +125.08 (+0.32%)
     
  • DAX

    18,772.85
    +86.25 (+0.46%)
     
  • Hang Seng

    18,963.68
    +425.87 (+2.30%)
     
  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     
  • NZD/JPY

    93.7530
    -0.0150 (-0.02%)
     

Pfizer’s Inlyta Expansion Thwarted by Failed Phase III Study

Pfizer’s Inlyta Expansion Thwarted by Failed Phase III Study

On April 11, 2018, Pfizer (PFE) stock witnessed a muted performance after its late-stage kidney trial for Inlyta failed to show any statistically significant improvement in disease-free survival compared to the placebo. The Phase III ATLAS trial evaluated the use of Inlyta (axitinib) as an adjuvant treatment for patients at high risk of RCC (renal cell carcinoma) recurrence after a nephrectomy.